10/31/2013 10:25:31 AM
MEMPHIS, Tenn.--(BUSINESS WIRE)--Meridian Life Science, Inc., (MLS) of Memphis, Tennessee, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), has been selected by the Centers for Disease Control and Prevention (CDC) to develop a process for manufacture of a rotavirus vaccine. Funding for this activity will be provided through a Small Business Innovation Research (SBIR) contract. Process development will focus on optimization of growth and yield of the virus in cell culture, inactivation of the rotavirus harvest and, finally, purification of the virus prior to formulation and filling. This initial SBIR will fund research and development activities at Meridian Life Science which could lead to scale up and manufacture of a rotavirus vaccine for use in clinical trials. Meridian Life Science is a contract manufacturer offering production of vaccines and challenge stocks which employ current Good Manufacturing Practices (cGMP) as described in 21 CFR Parts 210 and 211.
Help employers find you! Check out all the jobs and post your resume.
comments powered by